期刊文献+

临床药师对幽门螺杆菌阳性患者用药干预的随机对照试验 被引量:2

A Randomized Controlled Trail of a Pharmacy Intervention for Helicobacter Pylori Positive Patients
原文传递
导出
摘要 目的观察临床药师干预对幽门螺杆菌阳性患者的意义。方法选取我院就诊的幽门螺杆菌阳性患者,按患者疾病和年龄随机分为对照组和干预组。共纳入219例患者,完成对照组88例,干预组90例。对照组采用四联疗法7 d,医师按平时诊疗交代患者;干预组除以上诊疗外,临床药师对患者用药进行指导,并告知患者填写服药日记卡。2组患者分别于停药后30 d[14]C尿素呼气试验复查幽门螺杆菌根除率,停药后、停药后30 d、半年和1年电话随访。结果幽门螺杆菌根除率(对照组71.59%vs干预组78.89%)、随访调查2组腹痛、烧心、恶心、呕吐、嗳气等临床症状的复发率均无显著性差异。2组的药品不良反应发生率接近,但正确使用药物(对照组73.86%对比干预组94.44%)和对诊疗的满意度(对照组78.41%对比干预组95.56%)差异有统计学意义。结论临床药师的干预能提高幽门螺杆菌阳性患者正确用药和对诊疗的满意度。 OBJECTIVE To observe the importance of clinical pharmacist interventions on Helicobacter pylori positive patients. METHODS Helicobacter pylori positive patients were randomly divided into control or intervention groups according to the disease and age. 219 patients were under study. 88 patients were finished in control and 90 in intervention. Patients in the control group were treated with quadruple chemotherapy for 7 days. The administration accounts were executed by doctors as usual treatment. The intervention group was treated in addition to the above treatment, also the drug education was done by clinical pharmacists and the diary cards were issued. Helicobacter pylori eradication rates of all patients were tested by [141C urea breath test after the end of stopping all medicines 30 days. And telephone follow-up was done at the end of stopping all medicines, after 30 days, half a year and 1 year. RESULTS There was no significant difference in the 2 groups of Helicobacter pylori eradication rates(control 71.59% vs intervention 78.89%), relapse rates of epigastric pain, heartburn, nausea, vomiting and belching, the incidence of adverse reactions. But there were significant differences in the rates of proper use of medications (control 73.86% vs intervention 94.44%) and satisfaction for the treatments (control 78.41% vs intervention 95.56%). CONCLUSION Clinical pharmacist interventions on Helicobacter pylori positive patients improve their proper use of medications and satisfaction to the treatments.
出处 《中国现代应用药学》 CAS CSCD 2013年第5期526-529,共4页 Chinese Journal of Modern Applied Pharmacy
基金 广西柳州市应用技术研究与开发计划课题(2010030711) 广西壮族自治区卫生厅自筹经费科研课题(Z2010053)
关键词 幽门螺杆菌 阳性 临床药师 用药干预 Helicobacterpylori positive clinical pharmacists pharmaceutical intervention
  • 相关文献

参考文献8

  • 1VAKIL N, MEGRAUD F. Eradication therapy for Helicobacter pylori[J]. Gastroenterology, 2007, 133: 985- 1001.
  • 2Digestive Disease Branch of Chinese Medical Association, Helicobacter pylori bacteria grouplHelicobacter pylori research group. The 3'd Chinese Helicobacter pylori infection problems consensus report[J]. 胃肠病学,2008,13(1):42-46.
  • 3O'CONNOR J P, TANEIKE I, O'MORAIN C. Improving compliance with Helicobacter pylori eradication therapy: when and how[J]. Therap Adv Gastroenterol, 2009, 2(5): 273-279.
  • 4AL-EIDAN F A, MCELNAY J C, SCOTT M G, et al. Management of Helicobacter pylori eradication--the influence of structured counselling and follow-up[J]. Br J Clin Pharmacol, 2002, 53(2): 163-171.
  • 5FUNAKOSHI R, YOKOYAMA H, KAWAI N, et al. Effect of pharmaceutical care on diagnosis based on assessment of 13C-urea breath test for Helicobacter pylori infection[J]. Yakugaku Zasshi, 2012, 132(5): 601-607.
  • 6STEVENS V J, SHNEIDMAN R J, JOHNSON R E, et al. Helicobacter pylori eradication in dyspeptic primary care patients: a randomized controlled trial of a pharmacy intervention[J]. West J Med, 2002, 176(2): 92-96.
  • 7FURUTA T, SUGIMOTO M, SHIRAI N, et al. CYP2CI9 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with aproton pump inhibitor[J]. Pharmacogenomics, 2007, 8(9): 1199-210.
  • 8赵福军,王晓勇,王静,杨艳梅,张国新.CYP2C19基因多态性对亚洲人群中含质子泵抑制剂三联疗法幽门螺杆菌根除率影响的荟萃分析[J].胃肠病学,2008,13(10):611-615. 被引量:6

二级参考文献27

  • 1姜英杰,李瑜元,聂玉强,王红,沙卫红.根除幽门螺杆菌疗效与细胞色素氧化酶P450 2C19基因多态性的关系[J].中华消化杂志,2005,25(8):458-461. 被引量:8
  • 2Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet, 1984, 1 (8390): 1311-1315.
  • 3Buckley M, O'Morain C. Prevalence of Helicobacter pylori in non-ulcer dyspepsia. Aliment Pharmacol Ther, 1995, 9 Suppl 2: 53-58.
  • 4Marshall BJ, Windsor HM. The relation of Helicobacter pylori to gastric adenocarcinoma and lymphoma: pathophysiology, epidemiology, screening, clinical presentation, treatment, and prevention. Med Clin North Am, 2005, 89 (2): 313-344, viii.
  • 5Aoyama N, Tanigawara Y, Kita T, et al. Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori eradication in cytochrome P450 2C19 poor metabolizers. J Gastroenterol, 1999, 34 Suppl 11: 80-83.
  • 6Tanigawara Y, Aoyama N, Kita T, et al. CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori. Clin Pharmacol Ther, 1999, 66 (5): 528-534.
  • 7Dojo M, Azuma T, Saito T, et al. Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan. Dig Liver Dis, 2001, 33 (8): 671-675.
  • 8Furuta T, Shirai N, Takashima M, et al. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter priori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther, 2001, 69 (3): 158-168.
  • 9Hokari K, Sugiyama T, Kato M, et al. Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism. Aliment Pharmacol Ther, 2001, 15 (9): 1479-1484.
  • 10Inaba T, Mizuno M, Kawai K, et al. Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype. J Gastroenterol Hepatol, 2002, 17 (7): 748-753.

共引文献5

同被引文献21

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部